基于“糖肝共管”模式的代谢相关脂肪性肝病药物研究进展

打开文本图片集

Research Progress on Drugs for Metabolic Dysfunction-associated Steatotic Liver Disease Under "ComanagementofDiabetesandLiverDisease"ModelLIUAifang'，JIAXinyong²，LUOLei，YANGWenlongl. 'DepartmentofInfectiousDiseases，theScondAfliatedHospitalofanchangUniversity，Nanchang（33oo6）;Dent ofMedicalLaboratory，theSecondAffiliated HospitalofLuoheMedical Colege，Luohe，HenanProvince

Co-correspondence to： LUO Lei， Email： Zgll1990@163.com; YANG Wenlong， Email： wenlooyang@163.com

AbstractAgainst the backdrop of the global metabolicsyndrome pandemic，theincidence of type2 diabetes mellitus （T2DM）and metabolic dysfunction-asociated steatotic liver disease （MASLD）has beensteadilyincreasing.These twodiseases areclosely interrelatedand frequentlycoexist，rapidlyemerging asacritical public health issue worldwide. Theconceptof "co-managementof diabetesand liver disease"was first expounded in May 2O24.Todate，no drugs specifically indicated forthe treatmentof T2DMcombined with MASLDhave been approved for marketing.Thisarticle reviewedthe research progressondrugs for MASLD withintheframework of "co-managementofdiabetes and liverdisease" model，aiming to offer clinical references for the treatment of T2DM combined with MASLD.

KeyWordsMetabolic Dysfunction-Associated Steatotic LiverDisease；Diabetes Melitus，Type 2; Co-Management；Therapy

代谢相关脂肪性肝病（metabolicdysfunction-associatedsteatoticliverdisease，MASLD）以往称为非酒精性脂肪性肝病（nonalcoholic fattyliverdisease，NAFLD），是一类由于机体代谢功能紊乱造成脂质在肝脏内过度沉积的高度异质性疾病，其疾病谱包含单纯肝脂肪变性、代谢相关脂肪性肝炎（metabolicdysfunction-associated steatohepatitis，MASH）、肝纤维化、肝硬化和MASH相关肝细胞癌（hepatocellularcar-cinoma，HCC），目前已成为全球第一大肝病[1-2]。（剩余14238字）